AU2002312011B2 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses - Google Patents

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses Download PDF

Info

Publication number
AU2002312011B2
AU2002312011B2 AU2002312011A AU2002312011A AU2002312011B2 AU 2002312011 B2 AU2002312011 B2 AU 2002312011B2 AU 2002312011 A AU2002312011 A AU 2002312011A AU 2002312011 A AU2002312011 A AU 2002312011A AU 2002312011 B2 AU2002312011 B2 AU 2002312011B2
Authority
AU
Australia
Prior art keywords
virus
viruses
cells
mutations
flavivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002312011A
Other languages
English (en)
Other versions
AU2002312011A1 (en
Inventor
Joseph E. Blaney Jr
Kathryn A. Hanley
Ching-Juh Lai
Brian R. Murphy
Stephen S. Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
GOVERNMENT OF United States, AS REPRESENTED BY SECRETARY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOVERNMENT OF United States, AS REPRESENTED BY SECRETARY filed Critical GOVERNMENT OF United States, AS REPRESENTED BY SECRETARY
Publication of AU2002312011A1 publication Critical patent/AU2002312011A1/en
Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Application granted granted Critical
Publication of AU2002312011B2 publication Critical patent/AU2002312011B2/en
Priority to AU2008203275A priority Critical patent/AU2008203275B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2002312011A 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses Expired AU2002312011B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203275A AU2008203275B2 (en) 2001-05-22 2008-07-23 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29304901P 2001-05-22 2001-05-22
US60/293,049 2001-05-22
PCT/US2002/016308 WO2002095075A1 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203275A Division AU2008203275B2 (en) 2001-05-22 2008-07-23 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Publications (2)

Publication Number Publication Date
AU2002312011A1 AU2002312011A1 (en) 2003-05-08
AU2002312011B2 true AU2002312011B2 (en) 2008-04-24

Family

ID=23127420

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002312011A Expired AU2002312011B2 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
AU2008203275A Expired AU2008203275B2 (en) 2001-05-22 2008-07-23 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008203275A Expired AU2008203275B2 (en) 2001-05-22 2008-07-23 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Country Status (8)

Country Link
US (10) US7226602B2 (da)
EP (5) EP2290109B1 (da)
AU (2) AU2002312011B2 (da)
BR (2) BR122019026154B8 (da)
CA (5) CA2966716C (da)
DK (4) DK2292802T3 (da)
ES (4) ES2512715T3 (da)
WO (1) WO2002095075A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334310D1 (de) 2002-05-03 2010-11-04 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
EP1761277A1 (en) * 2004-06-14 2007-03-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
DE602006015807D1 (de) 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008157136A1 (en) * 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2294192A4 (en) * 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
ES2649020T3 (es) 2009-02-17 2018-01-09 Glaxosmithkline Biologicals S.A. Vacuna inactivada del virus del dengue con adyuvante libre de aluminio
WO2010130748A1 (en) * 2009-05-12 2010-11-18 Tibotec Pharmaceuticals Method for identifying inhibitors against dengue virus
JP5848243B2 (ja) 2009-06-01 2016-01-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対する免疫原性組成物
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
JP2012529934A (ja) * 2009-06-17 2012-11-29 ウッドフォード，ステファン 血行動態機能の測定
US8999675B2 (en) 2009-08-31 2015-04-07 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
WO2016037187A1 (en) * 2014-09-05 2016-03-10 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines
US10449243B2 (en) 2014-12-22 2019-10-22 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
WO2016115484A1 (en) * 2015-01-16 2016-07-21 Takeda Vaccines, Inc. Detection of particle-contained reverse transcriptase activity
EP3331559A4 (en) 2015-08-03 2019-03-06 The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
US20190194260A1 (en) * 2016-03-11 2019-06-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Live attenuated zika virus vaccine
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
CN115851627A (zh) * 2016-04-14 2023-03-28 新加坡国立大学 产生活减毒疫苗的快速方法
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
SG11202005251VA (en) 2017-12-07 2020-07-29 Merck Sharp & Dohme Formulations of dengue virus vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
EP1165129A1 (en) * 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-4 virus vaccine
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine

Also Published As

Publication number Publication date
CA3060687A1 (en) 2002-11-28
CA3114957A1 (en) 2002-11-28
US9707287B2 (en) 2017-07-18
EP2940154A1 (en) 2015-11-04
CA2966716C (en) 2019-11-26
EP2292802B1 (en) 2015-01-14
EP2940154B1 (en) 2019-05-22
US20090263424A1 (en) 2009-10-22
CA2755964A1 (en) 2002-11-28
EP2292802A3 (en) 2011-03-23
ES2512715T3 (es) 2014-10-24
EP2290109A2 (en) 2011-03-02
BR122019026154B1 (pt) 2020-11-24
AU2008203275B2 (en) 2011-11-10
USRE45053E1 (en) 2014-07-29
EP1402075B1 (en) 2012-11-14
WO2002095075A1 (en) 2002-11-28
US8632782B2 (en) 2014-01-21
ES2533085T3 (es) 2015-04-07
EP1402075A1 (en) 2004-03-31
DK2292802T3 (da) 2015-03-09
ES2399420T3 (es) 2013-04-01
DK1402075T3 (da) 2013-02-11
USRE45016E1 (en) 2014-07-15
US20050010043A1 (en) 2005-01-13
BR122019026154B8 (pt) 2021-07-27
BRPI0209943B8 (pt) 2021-05-25
DK2290109T3 (da) 2014-11-10
US20180008693A1 (en) 2018-01-11
USRE45123E1 (en) 2014-09-09
BR0209943A (pt) 2004-03-30
BRPI0209943B1 (pt) 2020-10-13
EP2290109A3 (en) 2011-03-16
US10500264B2 (en) 2019-12-10
US20150064214A1 (en) 2015-03-05
EP1402075A4 (en) 2005-05-11
US20200085939A1 (en) 2020-03-19
EP2290108A2 (en) 2011-03-02
EP2290108A3 (en) 2011-03-09
US8039003B2 (en) 2011-10-18
US20120114694A1 (en) 2012-05-10
EP2292802A2 (en) 2011-03-09
CA2448329C (en) 2011-10-25
US7226602B2 (en) 2007-06-05
EP2290109B1 (en) 2014-08-13
CA3114957C (en) 2022-02-08
US20070092534A1 (en) 2007-04-26
US11318196B2 (en) 2022-05-03
CA2755964C (en) 2017-06-27
CA2966716A1 (en) 2002-11-28
CA2448329A1 (en) 2002-11-28
ES2523168T3 (es) 2014-11-21
EP2290108B1 (en) 2014-07-23
AU2008203275A1 (en) 2008-08-14
DK2290108T3 (da) 2014-10-20
US7560118B2 (en) 2009-07-14
CA3060687C (en) 2021-05-04

Similar Documents

Publication Publication Date Title
US11318196B2 (en) Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
AU2002312011A1 (en) Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
AU2020200863B2 (en) Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT DETAILS BY DELETING JOSEPH E. BLANEY JR. AS CO-APPLICANT.

TH Corrigenda

Free format text: IN VOL 18, NO 5, PAGE(S) 1080 UNDER THE HEADING AMENDMENTS, SECTION 104 - AMENDMENTS MADE UNDER THE NAME THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2002312011, CORRECT THE NAME TO READ THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HANLEY, KATHRYN A.; MURPHY, BRIAN R.; WHITEHEAD, STEPHEN S.; BLANEY JR, JOSEPH E. AND LAI, CHINGJUH .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HANLEY, KATHRYN A.; MURPHY, BRIAN R.; WHITEHEAD, STEPHEN S.; BLANEY JR, JOSEPH E. AND LAI, CHING-JUH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired